Rigel Pharmaceuticals, Inc.
RIGL
$18.61
-$0.16-0.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.33M | 57.60M | 55.31M | 36.84M | 29.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.33M | 57.60M | 55.31M | 36.84M | 29.53M |
| Cost of Revenue | 12.85M | 11.42M | 14.21M | 8.35M | 8.05M |
| Gross Profit | 40.49M | 46.18M | 41.10M | 28.49M | 21.48M |
| SG&A Expenses | 27.72M | 29.52M | 27.04M | 28.05M | 28.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.56M | 40.94M | 41.25M | 36.39M | 36.50M |
| Operating Income | 12.77M | 16.66M | 14.06M | 447.00K | -6.97M |
| Income Before Tax | 11.51M | 15.22M | 12.42M | -1.03M | -8.25M |
| Income Tax Expenses | 65.00K | 881.00K | -- | -- | -- |
| Earnings from Continuing Operations | 11.45M | 14.34M | 12.42M | -1.03M | -8.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.45M | 14.34M | 12.42M | -1.03M | -8.25M |
| EBIT | 12.77M | 16.66M | 14.06M | 447.00K | -6.97M |
| EBITDA | 13.38M | 17.26M | 14.67M | 1.06M | -6.57M |
| EPS Basic | 0.64 | 0.81 | 0.71 | -0.06 | -0.47 |
| Normalized Basic EPS | 0.40 | 0.54 | 0.44 | -0.04 | -0.29 |
| EPS Diluted | 0.63 | 0.80 | 0.70 | -0.06 | -0.47 |
| Normalized Diluted EPS | 0.40 | 0.53 | 0.44 | -0.04 | -0.29 |
| Average Basic Shares Outstanding | 17.81M | 17.65M | 17.60M | 17.55M | 17.52M |
| Average Diluted Shares Outstanding | 18.17M | 17.99M | 17.65M | 17.55M | 17.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |